The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPlus Therapeutics (PSTV) has secured a Proprietary Laboratory Analyses (PLA) code from the American Medical Association (AMA) for its CNSide CSF tumor cell enumeration test. This milestone follows the recent appointment of Dr. Randy Goodman as VP of Value Strategy and HEOR to lead the company's commercial expansion. The new dedicated billing code is expected to streamline payer reimbursement processes and facilitate broader clinical adoption across the United States. By securing this code, the company strengthens its position in navigating value-based pricing and health policy for its lead assets, including REYOBIQ. This development marks a critical step in the company's transition toward full-scale commercialization. Analysts suggest that standardized reimbursement will be a key driver for the firm's long-term commercial viability and market penetration.